Moderate lifetime marijuana smoking not associated with lung function decline
the ONA take:
According to a new study published online in the journal Annals of the American Thoracic Society, researchers at Emory University in Atlanta, Georgia, have found that moderate lifetime marijuana use is associated with airway inflammation, but not significant changes in lung function.
For the study, researchers analyzed data from the National Health and Nutrition Examination Survey (NHANES). They identified over 5,000 adult survey participants with data on recent marijuana use and respiratory symptoms. Results showed that nearly 60% reported using marijuana at least once during their lifetime, and about 12% said they had used marijuana in the last month.
Among the 3,000 adult participants who had patterns of lifetime marijuana use, cumulative exposure of less than 20 joint-years was not linked with significant changes in lung function; however, more than 20 joint-years of marijuana exposure was associated with clinically significant changes in lung function.
The results do not show whether this change in lung function represents early lung function decline like that of long-term tobacco use. Researchers also found that marijuana smoking increased respiratory irritation, but the study could not determine whether those symptoms were permanent.
The researchers note that they did not assess an association between marijuana use and cancer.
Moderate lifetime marijuana use is associated with airway inflammation, but not significant changes in lung function.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|